Home » Stocks » SRNE

Sorrento Therapeutics, Inc. (SRNE)

Stock Price: $8.21 USD -0.18 (-2.15%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $8.34 +0.13 (1.58%) Jul 30, 7:58 PM
Market Cap 2.44B
Revenue (ttm) 46.52M
Net Income (ttm) -230.76M
Shares Out 280.60M
EPS (ttm) -0.91
PE Ratio n/a
Forward PE 1.10
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $8.21
Previous Close $8.39
Change ($) -0.18
Change (%) -2.15%
Day's Open 8.39
Day's Range 8.16 - 8.49
Day's Volume 2,738,048
52-Week Range 5.17 - 19.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Sorrento (SRNE) will provide updates on earnings and revenues when it releases second-quarter 2021 results.

4 days ago - Zacks Investment Research

Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 days ago - Zacks Investment Research

Not all meme stocks are "bad." But with retail investors beginning to realize the heavy lift that awaits them, you should avoid these seven.

Other stocks mentioned: AMC, CLOV, GME, NAKD, NEGG, SNDL
5 days ago - InvestorPlace

SAN DIEGO, July 23, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and Lee's Pharmaceutical Holdings Limited (HKEX: 950, “Lee's Pharm”) announced today that, on July 15,...

1 week ago - GlobeNewsWire

SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today its partner Escugen Biotechnology Co, Ltd. (“Escugen”) and Sorrento's subsidiary Leven...

1 week ago - GlobeNewsWire

Sorrento Therapeutics Inc (NASDAQ: SRNE) has started dosing COVID-19 patients in its Phase 2 efficacy trial.  This study uses a decentralized design where subjects are assessed and treated in their homes.

1 week ago - Benzinga

SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that COVID-19 patients have been dosed in its Phase 2 efficacy trial. Approximately 35...

1 week ago - GlobeNewsWire

SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has formed a subsidiary company based in Mexico City, Sorrento Therapeutics Me...

1 week ago - GlobeNewsWire

PALO ALTO, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), today announced complete enro...

1 week ago - GlobeNewsWire

Investors apparently weren't impressed by good news about the company's promising RTX.

3 weeks ago - The Motley Fool

The rally has more to do with the stock's pre-June circumstances than recent news.

3 weeks ago - The Motley Fool

The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) Phase 2 study of Resiniferatoxin (RTX) for moderate-to-severe osteoarthritis of the knee pain (OAK). The Phase 2 trial, a multi-center, ...

3 weeks ago - Benzinga

SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that the company has received FDA clearance to proceed with a Phase 2 clinical study o...

3 weeks ago - GlobeNewsWire

Rising numbers of new COVID-19 cases might have investors anticipating strong demand for the company's 15-minute test.

1 month ago - The Motley Fool

Earlier this month we discussed that the stock of Sorrento Therapeutics (NASDAQ: SRNE) is best avoided given the large rally it has seen in a short time period. While SRNE stock declined over 8% from le...

1 month ago - Forbes

Sorrento Therapeutics, Inc (NASDAQ:SRNE) shot up over 10% on June 24 after the company announced it received EUA approval and an import license from COFEPRIS for its rapid COVID-19 test, COVI-STIX. The ...

1 month ago - Benzinga

The company is setting up a subsidiary to launch its COVID-19 test in Mexico.

1 month ago - The Motley Fool

Sorrento Therapeutics Inc (NASDAQ: SRNE) is trading higher Thursday after the company received EUA approval and a product import license from COFEPRIS for its rapid COVID-19 test, COVI-STIX. COVI-STIX i...

1 month ago - Benzinga

SAN DIEGO, June 24, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that following its receipt of EUA approval from COFEPRIS (Comisión Federal para la Pro...

1 month ago - GlobeNewsWire

Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares moved higher Tuesday after the company announced Phase 2 Abivertinib clinical studies have completed patient enrollment in the U.S. and Brazil. The compa...

1 month ago - Benzinga

SAN DIEGO, June 22, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced a broad multi-year Cooperative Research and Development Agreement (CRADA) with NAMRU-3...

1 month ago - GlobeNewsWire

Sorrento Therapeutics Inc (NASDAQ: SRNE) has completed enrollment for its Phase 2 trial of Abivertinib in hospitalized COVID-19 patients in Brazil.  This study completion follows the recently completed ...

1 month ago - Benzinga

SAN DIEGO, June 22, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced completion of enrollment for its Phase 2 clinical trial of Abivertinib in hospitalized...

1 month ago - GlobeNewsWire

Although many indicators suggest the market is stretched, if you want to live dangerously, consider these high-risk, high-reward stocks. The post 7 High-Risk, High-Reward Stocks to Buy If You Have an Ir...

Other stocks mentioned: AMD, AUY, COIN, ENBL, SAVE, SOLO
1 month ago - InvestorPlace

Meme stocks continue to be a thing, despite confounding analysts who are questioning whether they can survive on Reddit steam alone. The post 7 Meme Stocks to Avoid So You Don't Get Caught Holding the B...

Other stocks mentioned: AMC, CLOV, CTRM, GME, GOEV, NAKD
1 month ago - InvestorPlace

The stock price of Sorrento Therapeutics (NASDAQ: SRNE), a clinical stage biopharma company that develops treatments for cancer and neurodegenerative diseases among others, has seen a solid 49% rise ove...

1 month ago - Forbes

The company got the green light to launch phase 2 testing in the U.K. for its experimental COVID-19 treatment.

1 month ago - The Motley Fool

Today, SRNE stock is on the move in a big way as investors price in two key announcements made by the company regarding clinical trials. The post SRNE Stock: The Big News Lifting Sorrento Therapeutics T...

1 month ago - InvestorPlace

Sorrento Therapeutics Inc (NASDAQ: SRNE) entered into a research collaboration agreement with Mayo Clinic to conduct human clinical proof of concept studies using the Sofusa Lymphatic Drug Delivery Syst...

1 month ago - Benzinga

The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) Phase 2 trial evaluating COVI-DROPS in newly diagnosed COVID-19 infected patie...

1 month ago - Benzinga

If analysts are right, these stocks offer implied upside ranging from 105% to as much as 216%.

Other stocks mentioned: CCHWF, MARA
1 month ago - The Motley Fool

SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Medicines and Healthcare products Regulatory Agency (MHRA), the United Kingdo...

1 month ago - GlobeNewsWire

SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced a research collaboration agreement with Mayo Clinic to conduct human clinical proof of...

1 month ago - GlobeNewsWire

SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun”), a license and develo...

1 month ago - GlobeNewsWire

SAN DIEGO and STOCKHOLM, Sweden, June 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Company has entered into an additional collaborative ag...

1 month ago - GlobeNewsWire

The biotech could play an important role in the battle against cancer and autoimmune diseases.

1 month ago - The Motley Fool

The shares of Sorrento Therapeutics Inc (NASDAQ:SRNE) are up 6.1% to trade at $8.10 at last check, after news that the company has initiated the start of its Covid-19 test roll-out in Mexico.

1 month ago - Schaeffers Research

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has completed the acquisition of ACEA Therapeutics Inc. (“ACEA”).

1 month ago - GlobeNewsWire

The pandemic bolstered many stocks to buy. But with cases fading, this narrative is now questionable.

Other stocks mentioned: APT, GILD, IBIO, INO, NVAX, QDEL
2 months ago - InvestorPlace

Sorrento Therapeutics Inc (NASDAQ: SRNE) reported positive initial results from the Phase 1B study of its Sofusa Lymphatic Delivery System administering Amgen Inc's (NASDAQ: AMGN) Enbrel for rheumatoid ...

2 months ago - Benzinga

SAN DIEGO, May 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Ph...

2 months ago - GlobeNewsWire

SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the first patient has been treated in a Phase 1b proof-of-concept, open-label stud...

2 months ago - GlobeNewsWire

Sorrento Therapeutics (SRNE) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

2 months ago - Zacks Investment Research

The FDA has signed off  Sorrento Therapeutics Inc's (NASDAQ: SRNE) IND to proceed with a Phase 2a study for STI-3031 for advanced urothelial carcinoma. STI-3031 is based on Sorrento's G-MAB library that...

3 months ago - Benzinga

SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Over the last several months, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") and its development partners have advanced into clinical development (P...

3 months ago - GlobeNewsWire

Hint: It's not because of anything the company said or did.

3 months ago - The Motley Fool

Sorrento Therapeutics Inc (NASDAQ: SRNE) has announced data from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) infusions to treat COVID-19 induced acute respir...

3 months ago - Benzinga

Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares lost ground Monday with no evident explanation. The stock was trending on StockTwits.

3 months ago - Benzinga

PALO ALTO, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- Scilex Holding (“Scilex”), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”), has received a supplemental new drug ap...

3 months ago - GlobeNewsWire

Which stock has more potential for growth over the next year? Let's look to the stars for an answer.

Other stocks mentioned: VIR
3 months ago - The Motley Fool

About SRNE

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody appr... [Read more...]

Industry
Biotechnology
Founded
2006
CEO
Henry Ji
Employees
502
Stock Exchange
NASDAQ
Ticker Symbol
SRNE
Full Company Profile

Financial Performance

In 2020, SRNE's revenue was $39.99 million, an increase of 27.21% compared to the previous year's $31.43 million. Losses were -$298.46 million, 2.19% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for SRNE stock is "Strong Buy." The 12-month stock price forecast is 28.00, which is an increase of 241.05% from the latest price.

Price Target
$28.00
(241.05% upside)
Analyst Consensus: Strong Buy